Rosiglitazone
- Generic Name
- Rosiglitazone
- Brand Names
- Avandamet, Avandia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O3S
- CAS Number
- 122320-73-4
- Unique Ingredient Identifier
- 05V02F2KDG
- Background
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellula...
- Indication
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 363
- Registration Number
- NCT00343980
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00337350
- Locations
- 🇺🇸
Massachusetts General Hospital Schizophrenia Program, Boston, Massachusetts, United States
AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone
- Conditions
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 245
- Registration Number
- NCT00333723
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 576
- Registration Number
- NCT00333151
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Windsor, Canada
Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 719
- Registration Number
- NCT00331487
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
- Conditions
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 630
- Registration Number
- NCT00329225
- Locations
GSK Investigational Site
Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 28
- Registration Number
- NCT00324675
- Locations
- 🇩🇪
University hospital Dresden, Dresden, Germany
The Effect Of AVANDIA On The Late Asthmatic Response
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT00318630
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1041
- Registration Number
- NCT00318422
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey
Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2006-09-21
- Lead Sponsor
- Herlev Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00309660
- Locations
- 🇩🇰
Dept. Gastroenterology C, Herlev University Hospital, Herlev, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.